The prospective cohort study on differentiation and treatment of membranous nephropathy by Wenyang Huaji method

Recruiting

Conditions: N05.2

Registration Number: DRKS00022948

Lead Sponsor: Beijing Hospital of Traditional Chinese Medicine

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Recruiting

Sex: All

Target Recruitment: 296

Inclusion Criteria

?Conforms to the MN diagnostic criteria.
?Conforms to the diagnostic criteria of Shaoyin Taiyin syndrome.
?The patient has signed the informed consent.
?Between the ages of 18 and 75.
?CKD stage I-III, eGFR>30ml/min, serum albumin >15g/L.

Exclusion Criteria

?Progressive membranous nephropathy (progressive decrease of renal function;Kidney biopsy showed necrotizing capillaritis and > 50% large crescent), accompanied by IgA nephropathy, diabetic nephropathy and other kidney diseases.
?Confirmed hepatitis B, systemic lupus erythematosus, tumor, drug damage and other factors secondary and need to actively treat the primary disease, such as active hepatitis B and persistent liver function test transaminase abnormalities, or anti-nuclear antibodies, double Abnormal strand DNA, ANCA or other indicators of immune disease.
?With acute central nervous system disease, severe gastrointestinal disease, a history of HIV infection, a history of mental illness or a history of malignancy.
?With other organ diseases and dysfunction, and with life-threatening complications such as severely infected persons.
?Pregnant or lactating women.
?Other clinical trials are under study.

Study & Design

Study Type: observational

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
To evaluate the efficacy of Mahuang Fuzi Tang and Shenzhuo Tang in treating MN. Patients were followed up once every 28 days since enrollment, with no more than 5 days before and after the enrollment, and each case was followed up at least 18 times, or until the death of the patient or the occurrence of a decrease in the glomerular filtration rate to 50%, or the occurrence of cardiovascular and cerebrovascular events. At each follow-up, we collected the current symptoms of the patients, as well as 24-hour urinary protein quantification and serum albumin values, and compared them with the status before enrollment to see whether the patients were in remission or not.

Secondary Outcome Measures

Name	Time	Method
To evaluate the safety of Mahuang Fuzi Tang and Shenzhuo Tang in treating MN. Patients were followed up once every 28 days since enrollment, with no more than 5 days before and after the enrollment, and each case was followed up at least 18 times, or until the death of the patient or the occurrence of a decrease in the glomerular filtration rate to 50%, or the occurrence of cardiovascular and cerebrovascular events. At each follow-up, we will collect the patients' liver function, renal function and electrolytes, and compare them with the status before enrollment, so as to understand whether the patients have liver and kidney function injury and other adverse reactions.